In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
What are Cancer Neoantigens? The Link Between Neoantigens and Immunotherapy – What's New in GU?
Unleashing the power of DNA: fighting cancer with tailored vaccines
Turning cold tumors into hot tumors by improving T-cell infiltration
Tumor Antigen Targets for Personalized Adoptive T Cell Therapies
Frontiers The Clinical Application of Neoantigens in Esophageal Cancer
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges, Biomarker Research
Targeting NRP2-VEGF to overcome immunosuppression and chemotherapy resistance in aggressive cancers
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells, Molecular Cancer
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells, Molecular Cancer
CD4+ T cells wear many hats
Silencing TAP makes the tumor a little louder
